Healthcare in Personal Injury Schemes

Summary of preliminary findings for NSW Workers Compensation and Compulsory Third Party schemes

State Insurance Regulatory Authority Final 11 September 2019



Table of Contents

1.	Introd	luction	3
	1.1	Background and scope	3
	1.2	Purpose of this document	3
2.	Execu	tive Summary	4
3.	Summ	nary of key observations for NSW Workers Compensation (WC) scheme	5
	3.1	Interjurisdictional comparison of WC schemes	5
	3.2	Dimension of medical spend	6
	3.3	Medical cost dynamics	7
4.	Summ	nary of key observations for NSW Compulsory Third Party (CTP) scheme	8
	4.1	Interjurisdictional comparison of CTP schemes	8
	4.2	Dimension of medical spend	9
	4.3	Medical cost dynamics	9
Арр	endix A	Glossary	11
Арр	endix B	Reliance and limitations	12

Disclaimer: Consistent with our statement of work, our report has been completed solely for the benefit of the State Insurance Regulatory Authority (SIRA) and EY has not been engaged to act, and has not acted, as advisor to any other party. Accordingly, EY makes no representations as to the appropriateness, accuracy or completeness of the report for any other party's purposes. Our work has been limited in time and scope and in completing the Fundamental Review we have relied on information provided by SIRA, the reliance and limitations of our Report are set out in Appendix B.

A member firm of Ernst & Young Global Limited Liability limited by a scheme approved under Professional Standards Legislation

1. Introduction

1.1 Background and scope

The State Insurance Regulatory Authority (SIRA) has observed increasing trends in service utilisation for medical attendances, private hospital services, orthopaedic surgery, neurosurgery and pain management clinics.

In response, SIRA is seeking to undertake a review of healthcare across the NSW Workers Compensation (WC) and Compulsory Third Party (CTP) personal injury schemes it regulates. The requirement to undertake this work arises from the legislated principle objectives of SIRA in the State Insurance and Care Governance Act 2015 No 19 (the Act) to: minimise cost to the community of workplace injuries and injuries arising from motor accidents; and to promote efficiency, effectiveness and viability of the schemes.

To support this work, SIRA engaged Ernst & Young (EY) in May 2019 to assist with preliminary analysis of the most significant areas of expenditure by volume. This analysis included: an interjurisdictional benchmarking comparison of medical costs fee setting regimes and fee regulation policy; an environmental scan to dimension medical costs in the NSW health system and the relative size of workers' compensation and CTP insurance spend; and analysis of medical spend dynamics.

1.2 Purpose of this document

The purpose of this document is to outline preliminary findings for NSW Workers Compensation and Compulsory Third-Party personal injury schemes for public consultation.

This document summarises key observations from EY's preliminary analysis of WC and CTP schemes including:

- i) An Interjurisdictional comparison of fee arrangements between New South Wales, Victoria, Queensland and the Comcare scheme
- ii) Dimension of medical spend within the NSW WC and CTP schemes as a proportion of the NSW Government and Non-Government recurrent expenditure based on publicly available data from the Australian Institute of Health and Welfare (AIHW)
- iii) Medical cost dynamics including trends, superimposed inflation and variations between providers, insurers and patient cohorts

2. Executive Summary

Preliminary analysis identified the following observations relevant to the NSW Workers Compensation (WC) scheme (see section 4 for additional detail):

- 1. Interjurisdictional comparison of WC schemes
 - ► Fee schedules in the NSW scheme are linked to the relatively higher AMA rates, with loadings compared QLD and Comcare, which use the AMA rates (with no loadings), and VIC which uses MBS fee schedules
 - Prices for public admitted and emergency care services in the NSW scheme are based on ABF and use the National Efficient Price (NEP) compared to other schemes with state-specific models referencing relatively lower prices
 - ► The NSW WC scheme will reimburse 'reasonably necessary' costs as per legislation. Other schemes use differing tests for costs such as 'reasonable and necessary' and provide relatively more guidance in relation to the process to determine where tests for costs are met (e.g., reference to clinical frameworks and guidelines, etc.)
- 2. Dimension of medical spend
 - The market share of total health expenditure in NSW that the scheme commissions is 1.2% of NSW Government and Non-Government recurrent expenditure¹
- 3. Medical cost dynamics
 - Service utilisation is identified as a key driver of increase in medical expenditure

Additionally, the following observations are relevant to the NSW Compulsory Third Party injury (CTP) scheme (see section 5 for additional detail):

- 1. Interjurisdictional comparison of CTP schemes
 - There are no fee orders but the AMA rates are used as the limit for treatment and care expenses in NSW. The Victorian scheme uses TAC-determined fee schedules that state maximum fees payable. The NSW scheme is estimated to have overall higher fee rates than the Victorian scheme
 - Prices for public admitted and emergency care services in the NSW scheme are based on ABF and use the national price compared to other schemes that use state-specific models with referencing relatively lower prices
 - ► The NSW CTP scheme will reimburse 'reasonable and necessary' costs as per legislation. Other schemes provide relatively more guidance in relation to the process and steps in determining where tests for costs are met (e.g., reference to clinical frameworks and guidelines, etc.)
- 2. Dimension of medical spend
 - The market share of total health expenditure in NSW that the scheme commissions is 1.1% of NSW Government and Non-Government recurrent expenditure¹
- 3. Medical cost dynamics
 - There is limited data available in relation to the new NSW CTP scheme as it has been in effect for 18 months, with claims still developing. Consequently, it has not been analysed to the same depth as the NSW WC scheme at this stage

¹ Based on 2014-15 Australian Institute of Health and Welfare (AIHW) data, this may not be representative of recent trends

A member firm of Ernst & Young Global Limited

Liability limited by a scheme approved under Professional Standards Legislation

3. Summary of key observations for NSW Workers Compensation (WC) scheme

3.1 Interjurisdictional comparison of WC schemes

<u>Key observation</u>: Fee schedules in the NSW scheme are linked to the relatively higher AMA rates, with loadings compared QLD and Comcare, which use the AMA rates (with no loadings), and VIC which uses MBS fee schedules.

- NSW scheme's fee schedules are linked to AMA rates (with loadings) and item numbers for most medical and surgical procedures
- ► This compares to fees in other jurisdictions:

	NSW	QLD	VIC	Comcare
Reference rate for maximum fees	AMA (with loadings)	AMA	MBS	AMA

► The item numbers and billing rules in the NSW fee schedules are also linked to the AMA schedule, with MBS rules adopted for some services e.g., spine surgery., This compares to Victoria, Queensland and South Australia which use the MBS items, explanations, definitions and rules

<u>Key observation</u>: Prices for public admitted and emergency care services in the NSW scheme are based on Activity Based Funding (ABF)² and use the National Efficient Price (NEP)³ compared to other schemes with state-specific models referencing relatively lower prices

► The NSW scheme uses the National Efficient Price for public hospital service fees compared to the other schemes that use state-specific models

	NSW	Victoria	Queensland	Comcare
Comparison of fee-	Admitted care:	Admitted care:	Inpatient care:	Critical care:
setting methods for public	NWAU ₁₈ ⁴ (1-11%) x NEP ₁₈₋₁₉ of \$5,012	WIES25 ⁵ x Base WIES Price ₂₀₁₈₋₁₉ of \$5,029	Fee varies by hospital, diagnosis and	\$3,934.95 (first 21 days)
hospital services		Emergency care: \$270	length of stay (e.g., \$7,359 x DRG cost weight for an inlier	\$1,720.95 (over 21 days)

² Method of funding public hospital services outline in Independent Hospital Pricing Authority Pricing Framework for Public Hospital Services 2019-20, <u>https://www.ihpa.gov.au/publications/pricing-framework-australian-public-hospital-services-2019-20</u>

A member firm of Ernst & Young Global Limited

³ National Efficient Price for public hospital services determined by the Independent Hospital Pricing Authority, refer https://www.ihpa.gov.au/publications/national-efficient-price-determination-2019-20

⁴ The National Weighted Activity Unit (NWAU) is the national unit for counting hospital service activity, based on the complexity of patients and legitimate variations in costs. The 'average' hospital service is equivalent to one NWAU.

⁵ The Weighted Inlier Equivalent Separation is part of the Victorian Department of Health's funding model and represents the cost weight of a separation that is adjusted for time spent in hospital.

Liability limited by a scheme approved under Professional Standards Legislation

NSW	Victoria	Queensland	Comcare
Emergency Department non- admitted care: NWAU ₁₈ x NEP ₁₈₋₁₉ of \$5,012 Rehabilitation & other fees apply.	Rehabilitation & other fees apply.	separation in Hospital A category) Emergency care & other fees apply.	Other inpatient: \$1,916.75 (first 21 days) \$1,067.00 (over 21 days) Other fees apply.

- Key observation: The NSW WC scheme will reimburse 'reasonably necessary' costs as per legislation. Other schemes use differing tests for costs such as 'reasonable and necessary' and provide relatively more guidance in relation to the process and steps in determining where tests for costs are met (e.g., reference to clinical frameworks and guidelines, etc.)
- ► The NSW WC scheme's tests for costs compares to the other jurisdictions as follows:

	NSW	QLD	VIC	Comcare
Test for reimbursing costs in the scheme	Reasonably necessary	Reasonable and necessary	Reasonable	Appropriate

► The criteria that underlies each of the tests differs, for example, the Comcare and Victorian schemes specify the consideration of endorsed clinical frameworks

3.2 Dimension of medical spend

<u>Key observation</u>: The market share of total health expenditure in NSW that the scheme commissions is 1.2% of NSW Government and Non-Government recurrent expenditure⁶

- ► Analysis of recent claims data from SIRA over the financial years 2014-15 to 2017-18 indicates a trend increase in expenditure observed in the scheme over those years. The trend points towards an emerging risk that the scheme will overtake the growth in the rest of the healthcare sector and experience an increase in market share.
- Historical healthcare expenditure within the scheme increased at a steady annual rate of approximately 0.9% from 1996-97 to 2014-15⁶
- Despite the increase in historical expenditure, its market share of NSW Government and Non-Government recurrent healthcare expenditure steadily declined from 2.2% in 1996-97 to 1.2% in 2014-15⁶. However, as per above, there may be a risk of this trend reversing
- Relatively larger growth in healthcare expenditure has been observed within the public and private healthcare systems (including in private health insurance), suggesting that the scheme has, historically, partially mitigated the utilisation and expenditure pressures*

⁶ This is based on 2014-15 Australian Institute of Health and Welfare (AIHW) data and may not be representative of more recent trends

A member firm of Ernst & Young Global Limited

Liability limited by a scheme approved under Professional Standards Legislation

3.3 Medical cost dynamics

Key observation: Service utilisation is identified as a key driver of increase in medical expenditure

- ► In FY2017-18, the increase in superimposed inflation is predominantly attributed to service utilisation growth
- ▶ The growth rate of service utilisation is at 7.7%, compared to 0.5% increase in unit cost
- ► The increase in service utilisation is due to both an increase of the breadth of services paid to a claimant and an increase in the frequency of service payments for a given service type
- The decline in unit costs is influenced by the slight decline in certain medical cost categories (e.g., surgery and private hospital services)

700 648 12 3 650 Total Expenditure (\$ million) 30 14 13 600 575 550 500 450 400 Impact of Inflation Change in # of Services per Active Claims Service Type Total Expenditure for FY2017 # of Different Service Change in Unit Cost Total Expenditure for FY2018 Types per Claim

Figure 1 Cost driver analysis for in-scope medical expenditure for FY2016-17 to FY2017-18

4. Summary of key observations for NSW Compulsory Third Party (CTP) scheme

4.1 Interjurisdictional comparison of CTP schemes

<u>Key observation</u>: There are no fee orders but the AMA rates are used as the limit for treatment and care expenses in NSW. The Victorian scheme uses TAC-determined fee schedules that state maximum fees payable. The NSW scheme is estimated to have overall higher fee rates than the Victorian scheme

- ► The Motor Accident Guidelines specify the AMA rates as the maximum amount payable for treatment and care in NSW although there are no fee schedules, compared to the Victorian scheme with TAC-determined fee schedules that state maximum fees payable
- ▶ The NSW scheme is estimated to have overall higher fee rates than the Victorian scheme

<u>Key observation</u>: Prices for public admitted and emergency care services in the NSW scheme are based on ABF and use the national price compared to other schemes that use state-specific models with referencing relatively lower prices

► The NSW scheme uses the National Efficient Price for public hospital service fees compared to the other schemes that use state-specific models

	NSW	Victoria	Queensland
Comparison of fee-setting methods for public hospital services	Admitted care: NWAU ₁₈ ⁷ (1-11%) x NEP ₁₈₋₁₉ of \$5,012 Emergency Department non-admitted care: NWAU ₁₈ x NEP ₁₈₋₁₉ of \$5,012 Rehabilitation & other fees apply.	Admitted care: WIES25 ⁸ x Base WIES Price ₂₀₁₈₋₁₉ of \$5,700 Emergency care: \$451 Rehabilitation & other fees apply.	Funded by MAIC grant to Queensland Health based on an apportionment of the MAIC Hospital & Emergency Services levy.

 ⁷ The National Weighted Activity Unit (NWAU) is the national unit for counting hospital service activity, based on the complexity of patients and legitimate variations in costs. The 'average' hospital service is equivalent to one NWAU.
⁸ The Weighted Inlier Equivalent Separation is part of the Victorian Department of Health's funding model and represents the

^o The Weighted Inlier Equivalent Separation is part of the Victorian Department of Health's funding model and represents the cost weight of a separation that is adjusted for time spent in hospital.

A member firm of Ernst & Young Global Limited

Liability limited by a scheme approved under Professional Standards Legislation

<u>Key observation</u>: The NSW CTP scheme will reimburse 'reasonable and necessary' costs as per legislation. Other schemes provide relatively more guidance in relation to the process and steps in determining where tests for costs are met (e.g., reference to clinical frameworks and guidelines, etc.)

► The NSW scheme's tests for costs compares to the other jurisdictions as follows:

	NSW	QLD	VIC
Test for reimbursing costs in the scheme	Reasonable and necessary	Reasonably and appropriately incurred	Reasonable

► The criteria that underlies each of the tests for either costs or services differs, for example, the and Victorian scheme specifies the consideration of the principles of the endorsed clinical framework when considering whether the treatment is reasonable and appropriate

4.2 Dimension of medical spend

<u>Key observation</u>: The market share of total health expenditure in NSW that the scheme commissions is 1.1% of NSW Government and Non-Government recurrent expenditure⁹

- ► Healthcare expenditure within the scheme has increased at an annual rate of approximately 4.1% from 1996-97 to 2014-15*
- Despite the increase in expenditure, its market share of NSW Government and Non-Government recurrent healthcare expenditure has remained relatively constant between the late 1990s and 2014-15 at around 1.1%*
- Relatively larger growth in healthcare expenditure has been observed within the public and private healthcare systems (including in private health insurance), suggesting that the scheme has, historically, partially mitigated the utilisation and expenditure pressures*

*This is based on 2014-15 Australian Institute of Health and Welfare (AIHW) data and may not be representative of more recent trends

4.3 Medical cost dynamics

<u>Key observation</u>: There is limited data available in relation to the new NSW CTP scheme as it has been in effect for 18 months, with claims still developing. Consequently, it has not been analysed to the same level of depth as the NSW WC scheme at this stage.

The top 3 sub-categories of expenditure are physiotherapy services (\$10 million), specialist surgeons (\$6 million) and specialist attendances (\$5 million) over the period January 2018 to March 2019

⁹ This is based on 2014-15 Australian Institute of Health and Welfare (AIHW) data and may not be representative of more recent trends

A member firm of Ernst & Young Global Limited

Liability limited by a scheme approved under Professional Standards Legislation

- An illustrative chart is included of the trend in medical expenditure from January 2018 to March 2019 for all medical cost categories
- ► However, the trends should be viewed with caution until the claims within the new scheme have developed sufficiently to facilitate detailed analysis of medical expenditure




Figure 2 Historical total medical expenditure in the NSW CTP scheme by medical cost categories

Appendix A Glossary

Term	Definition
ABF	Activity Based Funding
AIHW	Australian Institute of Health and Welfare
СТР	Compulsory Third Party
NEP	National Efficient Price
NWAU	National Weighted Activity Unit
SIRA	State Insurance Regulatory Authority
WEIS	Weighted Equivalent Inlier Separation
WC	Workers Compensation

Appendix B Reliance and limitations

Ernst & Young ("EY") was engaged on the instructions of the State Insurance Regulatory Authority ("Client") to conduct a review of healthcare in personal injury schemes, including an environmental scan to dimension medical costs in the NSW health system and the relative size of Workers Compensation and CTP insurance spend, and conduct interjurisdictional benchmarking for the inscope medical cost categories ("Project"), in accordance with the statement of work signed and dated 7 June 2019 and the Contract Agreement SIRA//6358/2016 between EY and SIRA dated 20 April 2017. In a subsequent phase of work, EY has been engaged to undertake preliminary stakeholder engagement with NSW WC and CTP insurers as part of the second phase of review, in accordance with the statement of work signed and dated 17 July 2019, and further analysis of healthcare trends in accordance with the amendment to the statement of work signed and dated 21 August 2019.

The outputs of EY's work are set out within this report ("Report"). You should read the Report in its entirety including any disclaimers and attachments. A reference to the Report includes any part of the Report. No further work has been undertaken by EY since the date of the Report to update it.

Our Report is limited in time and scope, other more detailed reviews or investigations may identify additional issues or considerations that this Report has not. The results of our work is limited by the availability and quality of data. The results of our work and procedures performed do not constitute an audit, a review or other form of assurance in accordance with any generally accepted auditing, review or other assurance standards, and accordingly we do not express any form of assurance.

In preparing this Report, EY has relied on information provided by the management of SIRA. EY has not conducted any audit, review or other form of verification of information provided by the management of SIRA. EY has not performed any independent verification of the accuracy or completeness of this information. EY does not accept any responsibility or liability for independently verifying any information we have obtained nor do we make any representation to the accuracy or completeness of information provided by the management of SIRA.

Unless otherwise agreed in writing with EY, third party access to this Report is made only on the following basis and in either accessing the Report or obtaining a copy of the Report any third party recipient agrees to the following terms.

- 1. Subject to the provisions of this notice, the Report has been prepared for the Client and may not be disclosed to any other party or used by any other party or relied upon by any other party without the prior written consent of EY
- 2. EY disclaims all liability in relation to any other party who seeks to rely upon the Report or any of its contents
- 3. EY has acted in accordance with the instructions of the Client in conducting its work and preparing the Report, and, in doing so, has prepared the Report for the benefit of the Client, and has considered only the interests of the Client. EY has not been engaged to act, and has not acted, as advisor to any other party. Accordingly, EY makes no representations as to the appropriateness, accuracy or completeness of the Report for any other party's purposes.
- 4. No reliance may be placed upon the Report or any of its contents by any party other than the Client. Any party receiving a copy of the Report must make and rely on their own enquiries in relation to the issues to which the Report relates, the contents of the Report and all matters arising from or relating to or in any way connected with the Report or its contents
- 5. The Report is confidential and must be maintained in the strictest confidence and must not be disclosed to any party for any purpose without the prior written consent of EY

A member firm of Ernst & Young Global Limited

Liability limited by a scheme approved under Professional Standards Legislation

- 6. No duty of care is owed by EY to any recipient of the Report in respect of any use that the recipient may make of the Report
- 7. EY disclaims all liability, and takes no responsibility, for any document issued by any other party in connection with the Project
- 8. A recipient must not name EY in any report or document which will be publicly available or lodged or filed with any regulator without EY's prior written consent, which may be granted at EY's absolute discretion
- 9. A recipient of the Report:
 - (a) may not make any claim or demand or bring any action or proceedings against EY or any of its partners, principals, directors, officers or employees or any other Ernst & Young firm which is a member of the global network of Ernst Young firms or any of their partners, principals, directors, officers or employees ("EY Parties") arising from or connected with the contents of the Report or the provision of the Report to the recipient
 - (b) must release and forever discharge the EY Parties from any such claim, demand, action or proceedings
- 10. In the event that a recipient discloses the Report to a third party in breach of this notice, it will be liable for all claims, demands, actions, proceedings, costs, expenses, loss, damage and liability made or brought against or incurred by the EY Parties, arising from or connected with such disclosure
- 11. In the event that a recipient wishes to rely upon the Report that party must inform EY and, if EY agrees, sign and return to EY a standard form of EY's reliance letter. A copy of the reliance letter can be obtained from EY. The recipient's reliance upon the Report will be governed by the terms of that reliance letter

EY | Assurance | Tax | Transactions | Advisory

About EY

EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.

EY refers to the global organisation and may refer to one or more of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organisation, please visit ey.com.

© 2019 Ernst & Young, Australia All Rights Reserved.

ED None. Ernst & Young is a registered trademark.

Our Report may be relied upon by the State Insurance Regulatory Authority (SIRA) pursuant to the terms of our statement of work dated 27 July 2019 and previously varied 21 August 2019 under the Contract Agreement SIRA//6358/2016 between EY and SIRA dated 20 April 2017. We disclaim all responsibility to any party for any loss or liability that any party may suffer or incur arising from or relating to or in any way connected with the contents of our report, the provision of our report to any party or the reliance upon our report by any party.

Liability limited by a scheme approved under Professional Standards Legislation.

ey.com